Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
252.8 CHF | +1.04% | +0.32% | -3.29% |
06-02 | Astra's Enhertu breast cancer trial shows 'unprecedented' results | RE |
06-02 | Astra's Enhertu delays breast cancer in patients with low HER2 levels | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- This company will be of major interest to investors in search of a high dividend stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's enterprise value to sales, at 3.28 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.29% | 206B | - | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
+9.78% | 210B | B- | ||
+6.17% | 164B | C+ | ||
-0.45% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RO Stock
- Ratings Roche Holding AG